Emerging studies on retatruded, a dual agonist for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, demonstrate encouraging findings in addressing weight gain and type 2 diabetic condition. Early information from clinical trials show notable diminutions in body weight and improved glucose control. Additional research is foc